Nonhematologic toxicities with imatinib in newly diagnosed chronic phase chronic myelogenous leukemia (CML) patients.26
Adverse Event . | All Grades (%) . | Grades 3/4 (%) . |
---|---|---|
Superficial edema | 53.2 | 0.9 |
Nausea | 42.5 | 0.4 |
Muscle cramps | 35.4 | 1.1 |
Musculoskeletal pain | 33.6 | 2.7 |
Rash | 31.9 | 2.0 |
Fatigue | 30.7 | 1.1 |
Diarrhea | 30.3 | 1.3 |
Headache | 28.5 | 0.4 |
Joint pain | 26.7 | 2.2 |
Abdominal pain | 23.4 | 2.0 |
Myalgia | 20.9 | 1.5 |
Nasopharyngitis | 19.2 | 0 |
Hemorrhage | 18.9 | 0.7 |
Dyspepsia | 15.1 | 0 |
Vomiting | 14.7 | 0.9 |
Pharyngolaryngeal pain | 14.2 | 0.2 |
Dizziness | 13.2 | 0.5 |
Cough | 12.5 | 0.2 |
URI | 12.5 | 0.2 |
Pyrexia | 11.8 | 0.5 |
Weight, increased | 11.6 | 0.7 |
Insomnia | 11.4 | 0 |
Depression | 8.9 | 0.5 |
Constipation | 7.6 | 0.7 |
Rigors | 6.9 | 0 |
Anxiety | 6.5 | 0.2 |
Dyspnea | 6.5 | 1.3 |
Pruritus | 6.5 | 0.2 |
Influenza-like illness | 6.4 | 0 |
Night sweats | 6.4 | 0.2 |
Anorexia | 4.7 | 0 |
Sweating, increased | 3.3 | 0 |
Alopecia | 2.2 | 0 |
Adverse Event . | All Grades (%) . | Grades 3/4 (%) . |
---|---|---|
Superficial edema | 53.2 | 0.9 |
Nausea | 42.5 | 0.4 |
Muscle cramps | 35.4 | 1.1 |
Musculoskeletal pain | 33.6 | 2.7 |
Rash | 31.9 | 2.0 |
Fatigue | 30.7 | 1.1 |
Diarrhea | 30.3 | 1.3 |
Headache | 28.5 | 0.4 |
Joint pain | 26.7 | 2.2 |
Abdominal pain | 23.4 | 2.0 |
Myalgia | 20.9 | 1.5 |
Nasopharyngitis | 19.2 | 0 |
Hemorrhage | 18.9 | 0.7 |
Dyspepsia | 15.1 | 0 |
Vomiting | 14.7 | 0.9 |
Pharyngolaryngeal pain | 14.2 | 0.2 |
Dizziness | 13.2 | 0.5 |
Cough | 12.5 | 0.2 |
URI | 12.5 | 0.2 |
Pyrexia | 11.8 | 0.5 |
Weight, increased | 11.6 | 0.7 |
Insomnia | 11.4 | 0 |
Depression | 8.9 | 0.5 |
Constipation | 7.6 | 0.7 |
Rigors | 6.9 | 0 |
Anxiety | 6.5 | 0.2 |
Dyspnea | 6.5 | 1.3 |
Pruritus | 6.5 | 0.2 |
Influenza-like illness | 6.4 | 0 |
Night sweats | 6.4 | 0.2 |
Anorexia | 4.7 | 0 |
Sweating, increased | 3.3 | 0 |
Alopecia | 2.2 | 0 |